Complete Genome Sequence of a CTX-M-15-Producing *Escherichia coli* Strain from the H30Rx Subclone of Sequence Type 131 from a Patient with Recurrent Urinary Tract Infections, Closely Related to a Lethal Urosepsis Isolate from the Patient’s Sister

Timothy J. Johnson,a Maliha Aziz,b,c Cindy M. Liu,b,c Evgeni Sokurenko,d Dagmara I. Kisiela,d Sandip Paul,d Paal Andersen,e James R. Johnson,f Lance B. Priceb,c

Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, Minnesota, USA; Department of Environmental and Occupational Health, George Washington University, Washington, District of Columbia, USA; Division of Pathogen Genomics, Translational Genomics Research Institute (TGen), Flagstaff, Arizona, USA; Department of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA; Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark; Veterans Affairs Medical Center and University of Minnesota, Minneapolis, Minnesota, USA

We report here the complete genome sequence, including five plasmid sequences, of *Escherichia coli* sequence type 131 (ST131) strain JJ1887. The strain was isolated in 2007 in the United States from a patient with recurrent cystitis, whose caregiver sister died from urosepsis caused by a nearly identical strain.

*Escherichia coli* sequence type 131 (ST131) is currently the most prevalent extraintestinal *E. coli* lineage (1). Its ST131–H30 sublineage accounts for most *E. coli* isolates that are fluoroquinolone resistant and produce extended-spectrum β-lactamases (ESBLs) (2). Carriage of *bla*_{CTX-M-15} is associated with the ST131–H30Rx sublineage within ST131–H30 (3). ST131–H30 is associated with recurrent urinary tract infections, pyelonephritis, and urosepsis (1, 4–7). We sequenced two *E. coli* clinical isolates from two adult sisters, one with recurrent *E. coli* cystitis, and the other with fatal *E. coli* urosepsis that developed after caring for her sister. We previously reported the complete genome sequence of the deceased sister’s fatal *E. coli* strain (JJ1886), from the ST131–H30Rx sublineage (8). Here, we present the complete genome sequence of the surviving sister’s *E. coli* strain (JJ1887), which is also from ST131–H30Rx and nearly identical to JJ1886. Whether the sisters’ distinct clinical outcomes are attributable to host response differences, strain-specific features, or other factors, the JJ1887 genome represents a valuable added resource for understanding the pathogenicity of the ST131–H30Rx lineage.

JJ1887 was sequenced on the PacBio platform (P5-C3 chemistry), which generated 66,442 raw PacBio reads (mean read length, 10,942 bp; total nucleotides, 764,654,567). The PacBio sequence reads were manually error corrected using Illumina short reads (125× coverage, TruSeq chemistry) using CLC Genomics Workbench version 7. The resultant data were assembled using the Hierarchical Genome Assembly Process (HGAP) version 3 in the PacBio single-molecule real-time (SMRT) Portal, which produced a circular chromosome and five closed plasmids, with a mean coverage of 118×. The short-read mapping was further analyzed with Delly (9) and the Northern Arizona SNP Pipeline (NASP) (http://TGenNorth.github.io/NASP). The verified sequences were annotated using Prokka 1.10 (10) and the NCBI Prokaryotic Genome Annotation Pipeline (PGAP). Antimicrobial resistance genes were identified using ResFinder 2.1 (11), and phage regions were identified using PHAST (12).

The complete genome of the JJ1887 chromosome comprises a 5,081,061-bp chromosome with a G+C content of 50.78%. It includes 4,773 coding sequences (CDSs), 89 tRNAs, 22 rRNA features, and 7 intact prophage regions, one of which (57.4 kb) harbors *bla*_{CTX-M-15}.

JJ1887 contains five plasmids, of which pJJ1887-1, -2, and -3 are identical to plasmids in JJ1886 (8). According to PlasmidFinder 1.3 (13), pJJ1887-1 (1,552 bp) is a Col(MG828) plasmid with two CDSs; plasmid pJJ1887-2 (5,167 bp) is a Col156 plasmid with five CDSs; pJJ1887-3 (5,631 bp) is a ColE1-like plasmid with five CDSs; pJJ1887-4 (107,507 bp) has both RepFIA and RepFII replicons, with 125 CDSs; and pJJ1887-5 (130,603 bp) has both RepFIB and RepFII replicons, with 158 CDSs. *bla*_{TEM-1B} in pJJ1887-4 and *bla*_{TEM-1B} in pJJ1887-5 confer resistance to β-lactams, and the *aac(6’)-Ib-cr* gene in pJJ1887-4 codes for fluoroquinolone resistance. pJJ1887-5 also carries genes conferring resistance to aminoglycosides (*aac(3)-Ia*), macrolides (*mph(A)*), tetracyclines (*tet(B)*), trimethoprim (*sfd(B)*), sulfonamides (*sul1*), and fluoroquinolones (*qepA*).

**Nucleotide sequence accession numbers.** The complete sequences of the chromosome and plasmids of *E. coli* JJ1887 have been deposited in GenBank under accession numbers CP014316 to CP014321.

**ACKNOWLEDGMENTS**

This material is based upon work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs,
grant 1I01 CX000192 01 (to J.R.J.); NIH grant RC4- AI092828 (to E.S. and J.R.J.) and R01AI106007 (to E.S.); the TGen Foundation (to L.B.P. and M.A.); the Statens Serum Institut (to P.A.); the Augustinus Fonden (to P.A.); and USAMRMC grant W81XWH-10-1-0753 (to L.B.P.).

Patricia Stogsdill, Lonny Yarmus, Rob Owens, John Quinn, and Karen Lolans facilitated the provision of *E. coli* JJ1887 and associated clinical data. Computational resources for PacBio assembly were provided through the Minnesota Supercomputing Institute.

The opinions presented here are those of the authors and do not represent the official policy or position of the U.S. Government or any of its agencies.

**FUNDING INFORMATION**

This work, including the efforts of James R. Johnson, was funded by Office of Research and Development, Medical Research Service, Department of Veterans Affairs (101CX000192). This work, including the efforts of Malilha Aziz and Lance B. Price, was funded by TGEN Foundation. This work, including the efforts of Paal Skytt Andersen, was funded by Statens Serum Institut. This work, including the efforts of Lance B. Price, was funded by USAMRMC. This work, including the efforts of Paal Skytt Andersen, was funded by Augustinus Fonden (Augustinus Foundation).

**REFERENCES**

1. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. *Escherichia coli* sequence type ST131 as the major cause of serious multidrug-resistant *E. coli* infections in the United States. Clin Infect Dis 51:286–294. http://dx.doi.org/10.1086/655932.
2. Banerjee R, Johnson JR. 2014. A new clone sweeps clean: the enigmatic emergence of *Escherichia coli* sequence type 131. Antimicrob Agents Chemother 58:4997–5004. http://dx.doi.org/10.1128/AAC.02824–14.
3. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV. 2013. The epidemic of extended-spectrum-beta-lactamase-producing *Escherichia coli* ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio 4:e00377-13. http://dx.doi.org/10.1128/mBio.00377-13.
4. Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe I, Baquero F, Canton R, Nordmann P. 2008. Dissemination of clonally related *Escherichia coli* strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 14:195–200.
5. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine MH, Debroc C, Robicsek A, Hansen G, Urban C, Platell J, Trott DJ, Zhanel G, Weissman SJ, Cookson BT, Fang FC, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko EV. 2013. Abrupt emergence of a single dominant multidrug-resistant strain of *Escherichia coli*. J Infect Dis 207:919–928. http://dx.doi.org/10.1093/infdis/jit933.
6. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Canica MM, Park YJ, Lavigne JP, Pitout J, Johnson JR. 2008. Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61:273–281.
7. Peirano G, Pitout JD. 2010. Molecular epidemiology of *Escherichia coli* producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 35:316–321.
8. Andersen PS, Stegger M, Aziz M, Contento-Cuomo T, Gibbons HS, Keim P, Sokurenko EV, Johnson JR, Price LB. 2013. Complete genome sequence of the epidemic and highly virulent CTX-M-15-producing H30-Rx subclone of *Escherichia coli* ST131. Genome Announc 1(6):e00988-13. http://dx.doi.org/10.1128/genomeA.00988-13.
9. Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. 2012. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28:i333–i339. http://dx.doi.org/10.1093/bioinformatics/bts378.
10. Seemann T, 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069. http://dx.doi.org/10.1093/bioinformatics/btu153.
11. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 67:2640–2644.
12. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST: a fast phage search tool. Nucleic Acids Res 39:W347–W352. http://dx.doi.org/10.1093/nar/gkr485.
13. Carattoli A, Zankari E, Garcia-Fernandez A, Volody Larsen M, Lund O, Villa L, Moller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother 58:3895–3903. http://dx.doi.org/10.1128/AAC.02412–14.